Dr. MiltieAtlas by Dr. Miltie™Nationwide Grant Intelligence
Verification Pending — official Grants.gov candidate (posted)
HT942526TERPCTA

DoW Toxic Exposures Clinical Trial Award

Official Grants.gov opportunity HT942526TERPCTA from Ebony S Simmons Grantor. Requires full eligibility, amount, controlling deadline, award-type and duplication QA before publication.

FundingApplicant-level ceiling not stated in the retrieved federal synopsis; verify in full NOFO.
Deadline2026-11-19 (official deadline clock time and time zone must be checked in NOFO)
Last verifiedAtlas review
Required next actionReview the official full announcement, amendments and submission portal requirements before applying.

Broad Eligibility

Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

Official funding announcement — preliminary draft

Funder: Ebony S Simmons Grantor

Opportunity number: HT942526TERPCTA

Official listed status: posted

Closing information: 2026-11-19 (official deadline clock time and time zone must be checked in NOFO)

Award disclosure: Applicant-level ceiling not stated in the retrieved federal synopsis; verify in full NOFO.

Applicant categories in federal synopsis: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

Federal synopsis

Summary: The fiscal year 2026 (FY26) Toxic Exposures Research Program (TERP) Clinical Trial Award (CTA) mechanism supports the advancement, execution, and analysis of clinical trials with the potential to have a significant impact on the prevention, treatment, or management of symptoms, diseases or conditions associated with or resulting from military-related toxic exposures. Proposed projects may range from small proof-of-concept clinical trials (e.g., pilot, first-in-human, phase 0) designed to demonstrate the feasibility or inform the design of more advanced trials, through large-scale trials (including pragmatic clinical trials) to determine efficacy in relevant patient populations.  Distinctive Features: To encourage applications that include meaningful and productive collaborations, the FY26 TERP CTA includes a Partnering Principal Investigator Option (PPIO). One Principal Investigator (PI) is identified as the initiating PI, and an additional PI may be identified as a Partnering PI. If recommended for funding, each PI will be named on separate awards. The intent is to support interdisciplinary partnerships, such as those between clinicians and research scientists, that will accelerate the movement of promising interventions/​knowledge products into clinical applications. Partnering should significantly advance the research beyond what would be possible through independent efforts. https://cdmrp.health.mil/pubs/press/2026/terppreann

Draft intake record. Eligibility, program terms, current amendments and applicant ceiling must be independently verified before publishing.

Official Grants.gov opportunity and NOFO

Source verificationOfficial government source · www.grants.govAtlas last verified this record during its latest review. Always use the funder's current application materials, amendments and portal instructions as the controlling source.View source and application materials ↗